Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 6Terminated 3Recruiting 2Unknown 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 12Neuroendocrine Tumors 5Neoplasm Metastasis 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Adenoma, Islet Cell 3Recurrence 2Meningioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thymus Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphangioleiomyomatosis 1Locally Advanced Thyroid Gland Carcinoma 1Kidney Neoplasms 1Hormone Receptor Positive Breast Cancer 1HR+/HER2- Advanced Breast Cancer 1Glioma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Gallbladder Neoplasms 1Disease Progression 1Colorectal Neoplasms 1

Interventions

Bevacizumab 47lenvatinib 37atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10Immune Checkpoint Inhibitors 9camrelizumab 8apatinib 8Oxaliplatin 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × Everolimus × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT04803318 2024-06-25

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡